Ftse Mib
33.577,42
-0,39%
DAX
18.155,24
-0,04%
S&P 500
5.477,90
0,16%
NASDAQ
17.805,16
0,49%
Bitcoin
60.980,72
-1,34%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Atossa Therapeutics Inc (ATOS) Atossa Therapeutics Inc (ATOS) Notizie

ATOS

Atossa Therapeutics (ATOS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATOS
DataOraFonteTitoloSimboloCompagnia
17/06/202414:30GlobeNewswire Inc.Atossa Set to Join Russell 3000® Index Effective June 28, 2024NASDAQ:ATOSAtossa Therapeutics Inc
05/06/202414:30GlobeNewswire Inc.Atossa to Present at the Sidoti Small-Cap Investor ConferenceNASDAQ:ATOSAtossa Therapeutics Inc
28/05/202414:30GlobeNewswire Inc.Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment ModelNASDAQ:ATOSAtossa Therapeutics Inc
24/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATOSAtossa Therapeutics Inc
23/05/202415:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ATOSAtossa Therapeutics Inc
15/05/202414:30GlobeNewswire Inc.Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
14/05/202422:46Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:ATOSAtossa Therapeutics Inc
13/05/202422:05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATOSAtossa Therapeutics Inc
13/05/202415:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATOSAtossa Therapeutics Inc
13/05/202415:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATOSAtossa Therapeutics Inc
13/05/202414:50GlobeNewswire Inc.Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ATOSAtossa Therapeutics Inc
10/05/202415:04Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ATOSAtossa Therapeutics Inc
10/05/202415:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ATOSAtossa Therapeutics Inc
07/05/202414:30GlobeNewswire Inc.Atossa Therapeutics Announces Support of New Breast Cancer Screening GuidelinesNASDAQ:ATOSAtossa Therapeutics Inc
29/04/202414:30GlobeNewswire Inc.Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-EndoxifenNASDAQ:ATOSAtossa Therapeutics Inc
15/04/202414:30GlobeNewswire Inc.Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerNASDAQ:ATOSAtossa Therapeutics Inc
11/04/202414:30GlobeNewswire Inc.Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare ConferenceNASDAQ:ATOSAtossa Therapeutics Inc
09/04/202417:59GlobeNewswire Inc.Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-EndoxifenNASDAQ:ATOSAtossa Therapeutics Inc
01/04/202422:00GlobeNewswire Inc.Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:ATOSAtossa Therapeutics Inc
19/03/202413:30GlobeNewswire Inc.Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer PatientNASDAQ:ATOSAtossa Therapeutics Inc
18/03/202413:30GlobeNewswire Inc.Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing RequirementsNASDAQ:ATOSAtossa Therapeutics Inc
12/03/202413:30GlobeNewswire Inc.Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of DirectorsNASDAQ:ATOSAtossa Therapeutics Inc
22/02/202414:30GlobeNewswire Inc.Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS StudyNASDAQ:ATOSAtossa Therapeutics Inc
07/02/202414:30GlobeNewswire Inc.Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
09/01/202414:30GlobeNewswire Inc.Atossa Therapeutics Issues Letter to ShareholdersNASDAQ:ATOSAtossa Therapeutics Inc
04/12/202314:30GlobeNewswire Inc.Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical DirectorNASDAQ:ATOSAtossa Therapeutics Inc
20/11/202314:30GlobeNewswire Inc.Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
15/11/202323:03Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ATOSAtossa Therapeutics Inc
15/11/202322:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATOSAtossa Therapeutics Inc
15/11/202322:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATOSAtossa Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATOS

La tua Cronologia

BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
SPM
Saipem
BIT
STMMI
ST Microelectronics
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
BPE
Bper Banca
BIT
RACE
Ferrari NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TEN
Tenaris
BIT
TIT
Telecom Italia
BIT
SRG
Snam
BIT
LDO
Leonardo
BIT
G
Generali
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network